How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Business Services · Forecast 2027–2033
Prostatic Artery Embolization for BPH Market
- By Procedure Setting: Hospital Outpatient Department, Ambulatory Surgery Centers, Specialty Clinics
- By Embolic Agent Type: Polyvinyl Alcohol (PVA) Particles, Tris-acryl Gelatin Microspheres, Hydrogel Microspheres, Calibrated Microspheres
- By Patient Age Group: 50-59 Years, 60-69 Years, 70-79 Years, 80 Years and Above
- By BPH Severity Level: Mild BPH, Moderate BPH, Severe BPH
- By Imaging Guidance Technique: Digital Subtraction Angiography (DSA), Cone Beam Computed Tomography (CBCT), Magnetic Resonance Imaging (MRI)
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - Hospital Outpatient Department leads By Procedure Setting at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 12 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
12 chapters · 279 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.66 →
- 11 Competitive Landscape 5 sections p.173 →
- 12 Company Profiles 12 players: SWOT & benchmarking p.181 →
Full report · locked preview
Everything inside the Prostatic Artery Embolization for BPH Market report
A complete, evidence-based study - 12 chapters and 117 sections covering market size, segmentation across 5 axes, regional analysis and 12 company profiles, forecast to 2033.
Segmentation covered
Procedure Setting 3
Embolic Agent Type 4
Patient Age Group 4
BPH Severity Level 3
Imaging Guidance Technique 3
Companies profiled
Boston Scientific Corporation
Cook Medical (a subsidiary of Cook Group)
Terumo Corporation
Merit Medical Systems Inc.
Medtronic plc
C.R. Bard (now part of BD - Becton
Dickinson and Company)
Siemens Healthineers
Philips Healthcare
Stryker Corporation
Becton
Dickinson and Company (BD)
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
12 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →Boston Scientific Corporation
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →Cook Medical (a subsidiary of Cook Group)
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →Terumo Corporation
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →Merit Medical Systems Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →Medtronic plc
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →C.R. Bard (now part of BD - Becton
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.184 →Dickinson and Company)
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.191 →Siemens Healthineers
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →Philips Healthcare
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →Stryker Corporation
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.209 →Becton
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.214 →Dickinson and Company (BD)
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.220 →Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Global · 2025–2033
$2,255M by 2033 · 4.8% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Hospital Outpatient Department52.6
- Ambulatory Surgery Centers23.7
- Specialty Clinics23.7
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$511.5M → $774.0M · 5.3%
Europe$356.5M → $460.9M · 3.3%
Asia Pacific$325.5M → $470.0M · 4.7%
Latin America$201.5M → $293.0M · 4.8%
Middle East and Africa$155.0M → $228.6M · 5.0%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →4.752026
4.762027
4.782028
4.802029
4.802030
4.822031
4.822032
4.842033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- Boston Scientific Corporation20.2
- Cook Medical (a subsidiary of Cook Group)16.4
- Terumo Corporation8.9
- Merit Medical Systems Inc.10.4
- Medtronic plc8.2
- C.R. Bard (now part of BD - Becton7.9
- Others28.0
Segment contribution to growth (%)
Fig. 18 · p.39 →Procedure Setting27.8%
Embolic Agent Type16.4%
Patient Age Group15.1%
BPH Severity Level20.3%
Imaging Guidance Technique20.3%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America34.8
- Europe20.7
- Asia Pacific21.1
- Latin America13.2
- Middle East and Africa10.3
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| Boston Scientific Corporation | 97 | 75 | 84 | 73 | 87 | 91 | 85 |
| Cook Medical (a subsidiary of Cook Group) | 73 | 77 | 71 | 79 | 78 | 83 | 77 |
| Terumo Corporation | 75 | 80 | 84 | 71 | 69 | 77 | 76 |
| Merit Medical Systems Inc. | 62 | 79 | 68 | 82 | 60 | 69 | 70 |
| Medtronic plc | 73 | 56 | 59 | 68 | 52 | 67 | 63 |
| C.R. Bard (now part of BD - Becton | 48 | 53 | 67 | 56 | 64 | 69 | 60 |
| Dickinson and Company) | 41 | 45 | 42 | 55 | 65 | 53 | 50 |
| Siemens Healthineers | 50 | 55 | 38 | 48 | 35 | 44 | 45 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- Boston Scientific Corporation
- Cook Medical (a subsidiary of Cook Group)
- Terumo Corporation
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| Boston Scientific Corporation | ✓ | ✓ | ◐ | ◐ | ◐ | ✓ |
| Cook Medical (a subsidiary of Cook Group) | ◐ | ◐ | ◐ | ◐ | ✓ | ◐ |
| Terumo Corporation | ◐ | ✓ | ✓ | ✓ | − | ◐ |
| Merit Medical Systems Inc. | − | ✓ | ✓ | ◐ | − | ◐ |
| Medtronic plc | ✓ | − | ◐ | ✓ | − | ✓ |
| C.R. Bard (now part of BD - Becton | ◐ | − | ◐ | − | ◐ | ◐ |
| Dickinson and Company) | − | − | − | ◐ | − | ◐ |
| Siemens Healthineers | − | ◐ | − | ◐ | − | − |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1Boston Scientific Corporation85
2Cook Medical (a subsidiary of Cook Group)77
3Terumo Corporation76
4Merit Medical Systems Inc.70
5Medtronic plc63
6C.R. Bard (now part of BD - Becton60
7Dickinson and Company)50
8Siemens Healthineers45
Competitive tiers
§8.4 · p.172 →Leader1
Set the pace on share, breadth and innovation.
Boston Scientific Corporation
Challenger3
Strong scale, closing on the leaders.
Cook Medical (a subsidiary of Cook Group)Terumo CorporationMerit Medical Systems Inc.
Contender2
Focused players with pockets of strength.
Medtronic plcC.R. Bard (now part of BD - Becton
Niche2
Specialists in a single segment or region.
Dickinson and Company)Siemens Healthineers
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Go-to-market strategy
Land Procedure Setting in North America, then scale across Prostatic Artery Embolization for BPH Market — a $310M beachhead inside a $4.99B market.
Beachhead (SOM)$310Mobtainable near-term
Serviceable (SAM)$2.05Breachable market
Primary motionPartner-led + digitalgo-to-market
Time to scale3 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion90 fit
Hospital Outpatient Department
Best fit — highest urgency & budget in Procedure Setting.
Economic buyer76 fit
Ambulatory Surgery Centers
Strong fit — clear ROI and a fast path to value.
End user66 fit
Specialty Clinics
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Procedure Setting in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add Embolic Agent Type & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + Patient Age Group
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales46%
Partner / channel29%
Digital / self-serve17%
Marketplaces8%
Positioning & messaging
§GTM 2 · p.194 →For Procedure Setting leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Prostatic Artery Embolization for BPH Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified45%
Sales qualified22%
Evaluation12%
Closed-won7%
$13.7KCAC
$81KLTV
5.9:1LTV : CAC
< 4 moCAC payback
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Investment thesis
Prostatic Artery Embolization for BPH Market is a resilient opportunity — $4.48B by 2033, compounding at 5.7%.
TAM · 2025$2.87Btoday
TAM · 2033$4.48Bforecast
CAGR5.7%2027–2033
Cumulative$32.6Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$4.48BTotal addressable market
SAM$1.61BServiceable available market
SOM$263MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →5.7% CAGR
Demand compounds through 2033, outpacing GDP across Procedure Setting.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Procedure Setting moving from early to mainstream — durable secular demand.
Consolidation upside
12+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$4.48BLarge & growingTAM by 2033 at 5.7% CAGR
$1.61BServiceable nowreachable with today’s model
$263MBeachhead winobtainable near-term share
12+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$3.50BBear3.7% CAGR
$4.48BBase5.7% CAGR
$5.74BBull7.6% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & Embolic Agent Type optionality
- Customer concentrationBroaden installed base beyond top accounts
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Board pack · executive summary
Prostatic Artery Embolization for BPH Market — a $10.6B market by 2033. Plan: grow share from 8.3% to 16.9%.
Market size · 2033$10.6Btotal addressable
Market CAGR8.6%2027–2033
Target share16.9%from 8.3% today
Revenue ambition$1.80Bby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 8.3% | 16.9% | Ahead |
| Revenue | $956M | $1.80B | On track |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | On track |
| Segment coverage | 3 of 5 axes | 5 of 5 axes | On track |
| Gross margin | 30.2% | 39.7% | At risk |
| Customer retention | 84.6% | 96.5% | Behind |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in Procedure Setting
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build Embolic Agent Type capability
A defensible second engine — invest in Embolic Agent Type to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Procedure Setting share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch Embolic Agent Type
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $192M capacity & capability investment
- Greenlight bolt-on M&A in Embolic Agent Type
- Authorise North America expansion plan
- Fund R&D program for Procedure Setting leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownOn track
- Competitive share lossAt risk
- Input-cost & supply riskOn track
- Regulatory / policy changeOn track
- Execution & talentBehind
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Sales deck · value proposition
Win the Prostatic Artery Embolization for BPH Market conversation — a $3.37B market you can size, segment and defend in minutes.
Market size · 2033$3.37Btotal opportunity
Growth7.8%CAGR to 2033
Addressable buyers1,399+accounts in scope
Typical ROI7.3×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Procedure Setting
Goal Grow share in Procedure Setting
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →7.3×return on cost, year one
< 2 mopayback period
$73K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
12+players profiled in this market
Coverage includes
Boston Scientific CorporationCook Medical (a subsidiary of Cook Group)Terumo CorporationMerit Medical Systems Inc.Medtronic plcC.R. Bard (now part of BD - BectonDickinson and Company)Siemens Healthineers+4 more
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Prostatic Artery Embolization for BPH Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
Prostatic Artery Embolization for BPH Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Business Services · scroll →Prosthetic Heart Valve Holder Market
Market size, share, segmentation and regional forecast.
$5.7B market · 2025 base year
View reportProsthetic Heart Valve Market
Market size, share, segmentation and regional forecast.
$2.6B market · 2025 base year
View reportProsthetic Heart Valve Procedures Market
Market size, share, segmentation and regional forecast.
$5.5B market · 2025 base year
View reportProsthetics Market
Market size, share, segmentation and regional forecast.
$824M market · 2025 base year
View reportProstrate Specific Antigen (Psa) Testing Market
Market size, share, segmentation and regional forecast.
$4.8B market · 2025 base year
View reportProtable Electrical Network Analyze Market
Market size, share, segmentation and regional forecast.
$4.8B market · 2025 base year
View reportProtable Laser Rangefinder Market
Market size, share, segmentation and regional forecast.
$994M market · 2025 base year
View reportProtable Veterinary Doppler Market
Market size, share, segmentation and regional forecast.
$5.8B market · 2025 base year
View reportProtease enzyme Market
Market size, share, segmentation and regional forecast.
$1.9B market · 2025 base year
View reportProtease Food Enzyme Market
Market size, share, segmentation and regional forecast.
$5.7B market · 2025 base year
View reportProtease for Animal Feed Market
Market size, share, segmentation and regional forecast.
$1.4B market · 2025 base year
View reportProtease in Animal Feed Market
Market size, share, segmentation and regional forecast.
$3.7B market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report is readable online in full. Downloadable formats are available as optional $99 add-ons: a formatted PDF and a fully editable XLSX containing all underlying data tables - so you can re-chart, re-model, or drop any figure straight into your own deck.